# 7 Acylamino 3 cephem 4 carboxylic acid derivatives, processes for the preparation of the same and pharmaceutical composition comprising the same.

## Abstract
1. A compound of the formula CHEM in which R 1 is thiadiazolyl, R 2 is carboxy lower alkyl or protected carboxy lower alkyl, R 3 is hydrogen, halogen or lower alkenyl, and R 4 is carboxy or a protected carboxy group, and pharmaceutically acceptable salts thereof, and processes for the preparation of the same and pharmaceutical compositions comprising the same in admixture with pharmaceutically acceptable carriers.

## Claims
What we claim is 1. A compound of the formula EMI28.1 in which Ri iS thiadiazolyl, R2 is carboxy lower alkyl or protected carboxy lower alkyl, R3 is hydrogen, halogen or lower alkenyl, and R4 is carboxy or a protected carboxy group, and pharmaceutically acceptable salts thereof. 2. A compound of claim 1, which is syn isomer. 3. A compound of claim 2, in which R1 is 1,2,4 thiadiazolyl or 1,2,5 thiadiazolyl. 4. A compound of claim 3, in which R2 is carboxy lower alkyl or esterified carboxy lower alkyl and R4 is carboxy or esterified carboxy. 5. A compound of claim 4, in which R2 is carboxy lower alkyl and R4 is carboxy. 6. A compound of claim 5, in which R1 is 1,2,4 thiadiazolyl and R3 is hydrogen. 7. A compound of claim 6, which is 7 2 carboxymethQxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 cephem 4 carboxylic acid syn isomer 8. A compound of claim 5, in which R1 is 1,2,4 thiadiazolyl and R3 is halogen. 9. A compound of claim 8, which is 7 2 carboxymethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylic acid syn isomer . 10. A compound of claim 5, in which R3 is lower alkenyl. 11. A compound of claim 10, which is 7 2 carboxymethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4 carboxylic acid syn isomer or 7 2 carboxymethoxyimino 2 1,2 ,5 thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4 carboxylic acid syn isomer . 12. A compound of claim 4, in which R2 is esterified carboxy lower alkyl and R4 is carboxy. 13. A compound of claim 12, in which R2 is lower alkoxycarbonyl lower alkyl. 14. A compound of claim 13, which is 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 cephem 4 carboxylic acid syn isomer or 7 2 tert butoxycarbonyl methoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylic acid syn isomer . 15. A compound of claim 4, in which R2 is esterified carboxy lower alkyl and R4 is esterified carboxy. 16. A compound of claim 15, in which R2 is lower alkoxycarbonyl lower alkyl and R4 is mono or di or triphenyl lower alkoxycarbonyl which may have nitro. 17. A compound of claim 16, which is p nitrobenzyl 7 f2 tert butcxcarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylate syn isomer , benzhydryl 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4 carboxylate syn isomer or benzhydryl 7 2 tert butoxycarbonylmethoxyimino 2 1,2, 5 thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4 carbcxylate syn isomer . 18. A pharmaceutical composition comprising, as active ingredients, the compound claimed in claim 1, in admixture with pharmaceutically acceptable carriers. 19. A method for treating infectious diseases caused by pathogenic microorganisms, which comprises administering the compound claimed in claim 1 to infected human being or animals. 20. Use of the compound of claim 1 or a pharmaceutically acceptable.salt thereof for treatment of microbial infections. 21. A process for preparing a compound of the formulaEMI30.1 in which R1 is thiadiazolyl, R2 is carboxy lower alkyl or protected carboxy lower alkyl, R3 is hydrogen, halogen or lower alkenyl, and R4 is carboxy or a protected carboxy group, or a salt thereof, which comprises 1 reacting a compound of the formulaEMI31.1 in which R3 and R4 are each as defined above, or its reactive derivative at the amino group or a salt thereof, with a compound of the formula EMI31.2 in which R1 and R2 are each as defined above, or its reactive derivative at the carboxy group or a salt thereof, to give the compound I as mentioned above or a salt thereof or 2 subjecting a compound of the formulaEMI31.3 in which Razzs protected carboxy lower alkyl, and R1 R3 and R4 RÚ, Rê and R are each as defined above. or a salt thereof, to removal reaction of the carboxy protective group in Ra2 to give a compound of the formula EMI32.1 in which Rb2 is carboxy lower alkyl, and R1, R3 and R4 are each as defined above, or a salt thereof or 3 subjecting a compound of the formula EMI32.2 in which Ra4 is a protected carboxy group, and R1, R2 and R3 are each as defined above, or a salt thereof, to removal reaction of the carboxy protective group for R4a to give a compound of the formulaEMI32.3 in which R1, R2 and R3 are each as defined above, or a salt thereof. 22. A process of claim 21, which comprises reacting a compound of the formula EMI33.1 in which R3 and R4 are each as defined in claim 21, or its reactive derivative at the amino group or a salt thereof, with a compound of the formula EMI33.2 in which R1 and R2 are each as defined in claim 21, or its reactive derivative at the carboxy group or a salt thereof, to give a compound of the formula EMI33.3 in which R1, R2, R3 and R4 are each as defined in claim 21, or a salt thereof. 23. A process of claim 21, which comprises subjecting a compound of the formula EMI33.4 in which R1, Ra, R3 and R4 are each as defined in claim 21, or a salt thereof, to removal reaction of the carboxy protective group in Ra2 to give a compound of the formula EMI34.1 in which Rl, Rb, R3 and R4 are each as defined in claim 21, or a salt thereof. 24. A process of claim 21, which comprises subjecting a compound of the formula EMI34.2 in which RI, R2, R3 and Ra are each as defined in claim 21, or a salt thereof, to removal reaction of the carboxy protective group for Ra to give a compound of the formula EMI34.3 in which R1, R2 and R3 are each as defined in claim 21, or a salt thereof.

## Description
7 ACYLAMINO 3 CEPHEM 4 CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITION COMPRIS ING THE SAME The present invention relates to novel 7acylamino 3 cephem 4 carboxylic acid derivatives and pharmaceutically acceptable salts thereof. More particularly, it relates to novel 7acylamino 3 cephem 4 carboxylic acid derivatives and pharmaceutically acceptable salts thereof, which have antimicrobial activity, to processes for the preparation of the same, to a pharmaceutical composition comprising the same, and to a method of using the same therapeutically in the treatment of infectious diseases in human being or animals. Accordingly, one object of the present invention is to provide novel 7 acylamino 3 cephem 4 carboxylic acid derivatives and pharmaceutically acceptable salts thereof, which are highly active against a number of pathogenic microorganisms and are useful as antimicrobial agents, especially for oral administration. Another object of the present invention is to provide processes for the preparation of novel 7acylamino 3 cephem 4 carboxylic acid derivatives and salts thereof. A further object of the present invention is to provide a pharmaceutical composition comprising, as active ingredients, said 7 acylamino 3 cephem 4carboxylic acid derivatives and pharmaceutically acceptable salts thereof. Still further object of the present invention is to provide a method of using said 7 acylamino 3 cephem4 carboxylic acid derivatives and pharmaceutically acceptable salt thereof in the treatment of infectious diseases by pathogenic microorganisms in human being or animals. The object 7 acylamino 3 cephem 4 carboxylic acid derivatives are novel and can be represented by the following general formulaEMI2.1 in which R1 is thiadiazolyl, R2 is carboxy lower alkyl or protected carboxyClower alkyl, R3 is hydrogen, halogen or lower alkenyl, and R4 is carboxy or a protected carboxy group. In the object compounds I and the starting compounds II and III mentioned below, it is to be understood that there may be one or more stereoisomeric pair s such as optical and or geometrical isomers due to asymmetric carbon atom and double bond in those molecules and such isomers are also included within the scope of the present invention. With regard to geometrical isomers in the object compounds I and the starting compounds III , it is to be noted that, for example, the object compounds I include syn isomer, anti isomer and a mixture thereof, and the syn isomer means one geometrical isomer having the partial structure represented by the following formulaEMI3.1 wherein R1 and R2 are each as defined above, and the anti isomer means the other geometrical isomer having the partial structure represented by the following formulaEMI3.2 wherein R1 and R2 are each as defined above. Suitable pharmaceutically acceptable salts of the object compounds I are conventional non toxic salts and may include a salt with a base such as a salt with an inorganic base, for example, an alkali metal salt e.g. sodium salt, potassium salt, etc. , an alkaline earth metal salt e.g. calcium salt, magnesium salt, etc. , an ammonium salt a salt with an organic base, for example, an organic amine salt e.g. triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N dibenzylethylenediamine salt, etc. , and the like. According to the present invention, the object compounds I and the pharmaceutically acceptable salts thereof can be prepared by the processes as illustrated by the following reaction schemes. 1 Process 1 EMI4.1 or its reactive derivative at or a salt thereof the amino group, or a salt thereof 2 Process 2 EMI4.2 or a salt thereof or a salt thereof 3 Process 3 EMI5.1 or a salt thereof or a salt thereof in which RÚ, Rê, R and R4 are each as defined above, Raê is protected carboxy lower alkyl, Rbê is carboxy lower alkyl, Ra4 is a protected carboxy group. Some of the starting compounds III used inProcess 1 are new and can be prepared, for example, by the following methods.Method A EMI5.2 or a salt thereof or a salt thereofDeaminationEMI5.3 EMI6.1 or a salt thereof or a salt thereof in which R5 is a protected carboxy group and R2 is as defined above.Method B EMI6.2 or a salt thereof III f or a salt thereof in which R2 is as defined above. In the above and subsequent description of the present specification, suitable examples and illustration of the various definitions to be included within the scope thereof are explained in details as follows. The term lower in the present specification is intended to mean a group having 1 to 6 carbon atoms, unless otherwise indicated. Suitable thiadiazolyl group may include 1,2,4thiadiazolyl i.e. l,2,4 thiadiazol 3 yl and 1,2,4thiadiazol 5 yl , 1,2,5 thiadiazolyl i.e. 1,2,5thiadiazol 3 yl , and the like, in which the preferred one is 1,2,4 thiadiazolyl and the most preferred one is l,2,4 thiadiazol 3 yl. Suitable lower alkyl moieties of the carboxy lower alkyl and protected carboxy lower alkyl groups may include straight or branched one such as methyl, ethyl, propyl, ispropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl and the like, in which the preferred one is C1 C4 alkyl, and the most preferred one is methyl. Suitable protected carboxy group and protected carboxy moiety in the protected carboxy lower alkyl group may include an esterified carboxy group which is conventionally used in penicilin or cephalosporin compounds at their 3rd or 4th position thereof. Suitable ester moiety in esterified carboxy group may include lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t butyl ester, pentyl ester, tertpentyl ester, hexyl ester, etc. , lower alkenyl ester e.g. vinyl ester, allyl ester, etc. , lower alkynyl ester e.g. ethynyl ester, propynyl ester, etc. , lower alkoxy lower alkyl ester e.g. methoxymethyl ester, ethoxymethyl ester, isopropoxymethyl ester, l methoxyethyl ester, l ethoxyethyl ester, etc. , lower alkylthio lower alkyl ester e.g. methylthiomethyl ester, ethylthiomethyl ester, ethylthioethyl ester isopropylthiomethyl ester, etc. , mono or di or trihalo lower alkyl ester e.g. chloromethyl ester, bromomethyl ester, 2 iodoethyl ester, 2,2,2 trichloroethyl ester, etc. , lower alkanoyloxy lower alkyl ester e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, isobutyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, l acetoxyethyl ester, l propionyloxyethyl ester, l acetoxypropyl ester, etc. , lower alkanesulfonyl lower alkyl ester e.g.mesylmethyl ester, 2 mesylethyl ester, etc. , ar lower alkyl ester which may have one or more substituent s such as mono or di or tri phenyl lower alkyl ester which may have one or more suitable substituent s e.g. benzyl ester, 4 methoxybenzyl ester, 4 nitrobenzyl ester, phenethyl ester, benzhydryl ester, trityl ester, bis methoxyphenyl methyl ester, 3,4 dimethoxybenzyl ester, 4 hydroxy 3,5 di t butylbenzyl ester, etc. , aryl ester which may have one or more suitable substituents e.g. phenyl ester, tolyl ester, t butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, salicyl ester, etc. , lower alkylsubstituted 2 oxo l,3 dioxolyl e.g. 5 methyl 2 oxo1,3 dioxol 4 yl, etc. , and the like. Preferred examples of carboxy lower alkyl forRê and Rbê thus defined may include carboxymethyl, 1 carboxyethyl, 2 carboxyethyl, 1 carboxypropyl, 3 carboxypropyl, l carboxy l methylethyl, 4 carboxybutyl, 5 carboxypentyl, 6 carboxyhexyl, and the like, in which the more preferred one is carboxy C1 C4 alkyl, and the most preferred one is carboxymethyl. Preferred examples of protected carboxy lower alkyl for Rê and Raê thus defined may include lower alkoxycarbonyl lower alkyl e.g. methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, tertbutoxycarbonylmethyl, pentyloxycarbonylmethyl, l tertbutoxycarbonylethyl, 2 tert butoxycarbonylethyl, l tert butoxycarbonylpropyl, 3 tert butoxyzarbonyl propyl, l tert butoxycarbonyl l methylethyl, 4 tertbutoxycarbonylbutyl, S tert butoxycarbonylpentyl, 6 tert butoxycarbonylhexyl, etc. , ar lower alkoxy carbonyl lower alkyl which may have nitro such as monoor di or triphenyl lower alkoxycarbonyl lower alkyl which may have nitro e.g. benzyloxycarbonylmethyl, p nitrobenzyloxycarbonylmethyl, benzhydryloxycarbonyl methyl, trityloxycarbonylmethyl, l benzhydryloxycarbonylethyl, 3 benzhydryloxycarbonylpropyl, 4 benzyloxycarbonylbutyl, 4 nitrobenzyloxycarbonylpentyl, benzhydryloxycarbonylhexyl, etc, , in which the more preferred one is C1 C5 alkoxycarbonyl C1 C3 alkyl, and the most preferred one is tert butoxycarbonylmethyl. Preferred examples of a protected carboxy group for R4 and Ra4 thus defined may include ar lower alkoxycarbonyl which may have nitro such as mono or di or triphenyl lower alkoxycarbonyl which may have nitro e.g. benzyloxycarbonyl, p nitrobenzyloxycarbonyl, benzhydryloxycarbonyl, trityloxycarbonyl, phenethyloxycarbonyl, phenylpro poxycarbonyl, phenylbutoxycarbonyl, phenylhexyloxycarbonyl, etc. , and the like, in which the more preferred one is mono or di or triphenyl Cl C3 alkoxyzarbonyl which may have nitro, and the most preferred one is benzhydryloxycarbonyl and p nitrobenzyloxycarbonyl. Suitable halogen may include fluoro, chloro, bromo, iodo, and the like, in which the preferred one is chloro. Suitable lower alkenyl group may include straight or branched one such as vinyl, l propenyl, allyl, l or 2 or 3 butenyl, l or 2 or 3 or 4 pentenyl, l or 2 or 3 or 4 or 5 hexenyl, 2 methyl 2 propenyl, and the like, in which the preferred one is C2 C5alkenyl, and the most preferred one is vinyl. Particularly, the preferred embodiment of the termRÚ is 1,2,4, thiadiazolyl and 1,2,5 thiadiazolyl that of the term Rê is carboxy lower alkyl that of the term R3 is hydrogen, halogen and lower alkenyl and that of the term R4 is carboxy. The processes for preparing the object compounds I of the present invention are explained in details in the following. 1 Process 1 The compound I or a salt thereof can be prepared by reacting the compound II or its reactive derivative at the amino group, or a salt thereof with the compound III or its reactive derivative at the carboxy group, or a salt thereof. Suitable reactive derivative at the amino group of the compound II may include Schiff s base type imino or its tautomeric enamine type isomer formed by the reaction of the compound II with a carbonyl compound such as aldehyde, ketone or the like a silyl derivative formed by the reaction of the compound II with a silylating agent such as bis trimethylsilyl acetamide, trimethylsilylacetamide, bis trimethylsilyl urea, or the like and the like. Suitable salt of the compound II may include the same one as those given for the object compounds I , and further an acid addition salt such as an organic acid salt e.g. acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc. , an inorganic acid salt e.g.hydrochloride, hydrobromide, sulfate, phosphate, etc. , or a salt with an amino acid e.g. aspartic acid, glutamic acid, etc. , and the like. Suitable reactive derivative at the carboxy group of the compound III may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. The suitable example may be an acid chloride, an acid azide a mixed acid anhydride with an acid such as substituted phosphoric acid e.g. diaikylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc. dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid e.g. pivalic acid, pentanoic acid, isopentanoic acid, 2 ethylbutyric acid or trichloroacetic acid, etc. or aromatic carboxylic acid e.g. benzoic acid, etc. a symmetrical acid anhydride an activated amide with imidazole, 4 substituted imidazole, dimethylpyrazole, triazole or tetrazole or an activated ester e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl CH3 2N CH ester, vinyl ester, propargyl ester, p nitrophenyl ester, 2,4 dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesyl phenyl ester, phenylazophenyl ester, phenyl thioester, p nitrophenyl thioester, p cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8 quinolyl thioester, etc. , or an ester with a N hydroxy compound e.g. N,N dimethylhydroxylamine, l hydroxy 2 lH pyridone, Nhydroxysuccinimide, N hydroxyphthalimide, l hydroxy6 chloro lH benzotriazole, etc. , and the like, and these reactive derivatives can optionally be selected from them according to the kind of the compound III to be used. Suitable salt of the compound III may include the same one as that given for the object compounds I The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate,N,N dimethylformamide, pyridine or any other organic solvents which do not adversely influence the reaction, or a mixture thereof. When the compound III is used in a free acid form or its salt form in this reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as carbodiimide compounds e.g. N,N diethylcarbodiimide, N,N diisopropylcarbodiimide, N,Nt dicyclohexylcarbodiimide, N cyclohexyl N morpholinoethylcarbodiimide,N cyclohexyl N 4 diethylaminocyclohexyl carbodiimide, N ethyl N 3 dimethylaminopropyl carbodiimide, N,N carbonylbis 2 methylimidazole keteneimine compounds e.g. pentamethyleneketene Ncyclohexylimine, diphenylketene N cyclohexylimine, ethoxyacetylene l alkoxy l chloroethylene trialkyl phosphite e.g. trimethyl phosphite ethyl polyphosphate isopropyl polyphosphate phosphorus oxychloride phosphorus trichloride thionyl chloride oxalyl chloride triphenylphosphine 2 ethyl 7 hydroxybenzisoxazolium salt 2 ethyl 5 m sulfophenyl isoxazolium hydroxide intra molecular salt l p chlorobenzenesulfonyloxy 6 chloro lH benzotriazole so called Vilsmeier reagent prepared by the reaction of N,N dimethylformamide with thionyl chloride, phosgene, phosphorus oxychloride, etc. or the like. The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate e.g. sodium bicarbonate, potassium bicarbonate, etc. , alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc. , alkaline earth metal carbonate e.g. magnesium carbonate, calcium carbonate, etc. , tri lower alkylamine e.g.trimethylamine, triethylamine, etc. , pyridine,N lower alkylmorphorine e.g. N methylmorphorine, etc. ,N,N di lower alkylbenzylamine e.g. N,N dimethylbenzylamine, etc. , and the like. The reaction temperature is not critical, and the reaction is usually carried out under from cooling to warming. 2 Process 2 The compound I b or a salt thereof can be prepared by subjecting the compound I a or a salt thereof to removal reaction of the carboxy protective group in Ra2. Suitable salt of the compounds I a and I b may include the same one as that given for the object compounds I . The present reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like. i Hydrolysis Hydrolysis is preferably carried out in the presence of a base or an acid, Suitable base may include an alkali metal hydroxide e.g. sodium hydroxide, potassium hydroxide, etc. , an alkaline earth metal hydroxide e.g. magnesium hydroxide, calcium hydroxide, etc. , an alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc. , an alkaline earth metal carbonate e.g. magnesium carbonate, calcium carbonate, etc. , an alkali metal bicarbonate e.g. sodium bicarbonate, potassium bicarbonate, etc. , and the like. Suitable acid may include an organic acid e.g.formic acid, acetic acid, propionic acid, trifluoroacetic acid, benzenesulfonic acid, p toluenesulfonic acid,etc. and an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc. . The acidic hydrolysis using trifluoroacetic acid is usually accelerated by addition of cation trapping agent e.g phenol, anisole, etc. . The reaction is usually carried out in a solvent such as water, methylene chloride, an alcohol e.g.methanol, ethanol, etc. , tetrahydrofuran, dioxane or any other solvents which do not adversely influence the reaction, or a mixture thereof. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under from cooling to warming ii Reduction Reduction can be applied preferably for the removal of the carboxy protective group such as 4nitrobenzyl, 2 iodoethyl, 2,2,2 trichloroethyl, or the like. The reduction method applicable for the removal reaction may include, for example, reduction by using a combination of a metal e.g. zinc, zinc amalgam, etc. or a salt of chrome compound e.g. chromous chloride, chromous acetate, etc. and an organic or inorganic acid e.g. acetic acid, propionic acid, hydrochloric acid, sulfuric acid, etc. and conventional catalytic reduction in the presence of a conventional metallic catalyst such as palladium catalysts e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc. , nickel catalysts e.g. reduced nickel, nickel oxide, Raney nickel, etc. , platinum catalysts e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc. , and the like. The reaction is usually carried out in a conventional solvent such as water, alkanol e.g.methanol, ethanol, propanol, etc. , dioxane, tetrahydrofuran, acetic acid or any other organic solvents which do not adversely influence the reaction, or a mixture thereof. The reaction temperature is not critical, and the reaction is usually carried out under from cooling to warming. The present process includes within the scope thereof a case that the protected carboxy group for R4 is transformed into the free carboxy group during the reaction. 3 Process 3 The compound I d or a salt thereof can be prepared by subjecting the compound I c or a salt thereof to removal reaction of the carboxy protective group for Ra4 Suitable salt of the compounds I c and I d may include the same one as that given for the object compounds I . The present reaction is carried out in accordance with a conventional method such as hydrolysis, reduction, or the like as explained in Process 2, and accordingly, the methods of Hydrolysis and Reduction, and the reaction conditions thereof e.g. reaction reagents, temperature, solvent, etc. can be referred to those of Process 2. The present process includes within the scope thereof a case that the protected carboxy moiety in the protected carboxy lower alkyl group for R2 is transformed into the free carboxy moiety during the reaction. The methods for preparing the new starting compounds III b to III f are explained in details in the subsequent Preparations. It is to be noted that, in the aforementioned reactions in Processes 1 to 3 or the post treatment of the reaction mixture therein, in case that the starting or object compounds possess an optical and or geometrical isomer s , it may occasionally be transformed into the other optical and or geometrical isomer s , and such cases are also included within the scope of the present invention. In case that the object compounds I have a free carboxy group for R2 and R4 it may be transformed into its pharmaceutically acceptable salts by a conventional method. The object compounds I and the pharmaceutically acceptable salts thereof of the present invention are novel and exhibit high antimicrobial activity, inhibiting the growth of a wide variety of pathogenic microorganisms including Gram positive and Gram negative microorganisms and are useful as antimicrobial agents, especially for oral administration. Now in order to show the utility of the object compounds I , the test data on the antimicrobial activity of the representative compound of the object compounds I of this invention are shown in the following.Test Compound 7 2 Carboxymethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 cephem 4 carboxylic acid syn isomer .Test Method in vitro Antimicrobial Activities. In vitro antibacterial activity was determined by the two fold agar plate dilution method as described below. One loopful of an overnight culture of each test strain in Trypticase soy broth 108 viable cells per ml was streaked on heart infusion agar HI agar containing graded concentrations of the test compound, and the minimal inhibitory concentration MIC was expressed in terms of ug mQ after incubation at 370C for 20 hours.Test Results EMI16.1 tb SEP Test SEP strains SEP SEP SEP MIC SEP g mQ SEP tb Escherichia SEP coli SEP 31 SEP 0.05 tb Klebsiella SEP pneumonia SEP 7 SEP 0.05 tb For therapeutic administration, the object compounds I and the pharmaceutically acceptable salts thereof of the present invention are used in the form of conventional pharmaceutical preparation which contains said compounds, as active ingredients, in admixture with pharmaceutically acceptable carriers such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral and external administration.The pharmaceutical preparations may be in solid form such as tablet, granule, powder, capsule, or liquid form such as solution, suspension, syrup, emulsion, lemonade and the like. If needed, there may be included in the above preparations auxiliary substances, stabilizing agents, wetting agents and other commonly used additives such as lactose, stearic acid, magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, and the like. While the dosage of the compounds I may vary from and also depend upon the age, conditions of the patient, a kind of diseases, a kind of the compounds I to be applied, etc. In general, amounts between 1 mg and about 4,000 mg or even more per day may be administered to a patient. An average single dose of about 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg, 2000 mg of the object compounds I of the present invention may be used in treating diseases infected by pathogenic microorganisms. The following examples are given for the purpose of illustrating the present invention. Preparation of the starting compound III Preparation 1 To a solution of 2 tert butoxyzarbonylmethoxyimino 2 5 amino 1,2,4 thiadiazol 3 yl acetic acid syn isomer 20 g in ethyl acetate 200 ml and tetrahydrofuran 100 ml was added dropwise a solution of diphenyldiazomethane in ethyl acetate 0,9m mole ml, 80 ml at ambient temperature, and the mixture was stirred for an hour. The reaction mixture was washed with a saturated aqueous sodium bicarbonate and an aqueous sodium chloride, and then dried over magnesium sulfate.The solution was evaporated to give benzhydryl 2 tert butoxycarbonylmethoxyimino 2 5 amino 1,2,4 thiadiazol 3 yl acetate syn isomer 15.0 g , mp 1640C dec. . IR Nujol 3400, 3250, 3100, 1740, 1630, 1530 cm 1 NMR DMSO d6, d 1.48 9H, s , 4.72 2H, s , 7.08 lH, s , 7.36 lOH, m , 8.26 2H, broad s .Preparation 2 A solution of t butyl nitrite 3.2 g in tetrahydrofuran 20 ml was added dropwise to a solution of benzhydryl 2 tert butoxyzarbonylmethoxy imino 2 5 amino l,2,4 thiadiazol 3 yl acetate syn isomer 10 g in tetrahydrofAran 100 ml at 50 to 530C under stirring, and the mixture was stirred at the same temperature for 25 minutes. The reaction mixture was poured into a mixture of ethyl acetate and water. The separated organic layer was washed with an aqueous sodium chloride and dried over magnesium sulfate. The solution was evaporated and the residue was subjected to column chromatography on silica gel.The elution was carried out with a mixture of benzene and ethyl acetate 19 1 and the eluatescontaining the object compound were evaporated to give benzhydryl 2 tert butoxycarbonylmethoxyimino 2 l,2,4 thiadiazol 3 yl acetate syn isomer 7.1 g , mp.139 to 1410C. IR Nujol 1740, 1600, 1490 cm 1 NMR DMSO d6, 6 1.42 9H, s , 4.80 2H, s ,7.12 lH,s , 7.38 lOH, m , 10.32 1H, s .Preparation 3 To a solution of benzhydryl 2 tert butoxycarbonyl methoxyimino 2 l,2,4 thiadiazol 3 yl acetate syn isomer 6.5 g and anisole 6.5 ml in methylene chloride 60 ml was added trifluoroacetic acid 13 ml at ambient temperature, and the mixture was stirred at the same temperature for 25 minutes. To the reaction mixture was added ethyl acetate and the solution was washed with water. To the separated organic layer was added water and the mixture was adjusted to pH 7.5 with 20 aqueous sodium carbonate. The separated aqueous layer was acidified to pH 2.0 with 10 hydrochloric acid. The acidified solution was saturated with sodium chloride and extracted with ethyl acetate. The ethyl acetate layer was washed with an aqueous sodium chloride, and dried over magnesium sulfate. The solution was evaporated and the residue was pulverized with diisopropyl ether and n hexane to give 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetic acid syn isomer 2.2 g , mp. 1370C dec. . IR Nujol 1740, 1600 cm 1 NMR DMSO d6, d 1.46 9H, s , 4.76 2H, s , 10.32 1H, s .Preparation 4 To a solution of 1,2,5 thiadiazol 3 yl glyoxylic acid 6 g in tetrahydrofuran 30 ml and water 30 ml was added tert butoxycarbonylmethoxyamine 8.37 g at ambient temperature. The mixture was adjusted to pH 4.5 5.0 with 4N aqueous sodium hydroxide and stirred at ambient temperature for 4 hours. The mixture was adjusted to pH 7.5 with 4N aqueous sodium hydroxide and washed with ethyl acetate 100 ml x 2 . The aqueous solution was acidified to pH 2.0 with 10 hydrochloric acid and extracted with ethyl acetate 100 ml x 2 .The organic layer was washed with an aqueous sodium chloride and dried over magnesium sulfate. The solution was evaporated in vacuo to give 2 tert butoxyvarbonylmethoxyimino 2 1,2,5 thiadiazol 3 yl acetic acid syn and anti mixture 10.02 g . IR Nujol 3450, 1720, 1700 cm 1 NMR DMSO d6, 6 1.48 9H, s , 4.73 2H, s , 4.82 2H, s , 8.88 1H, s , 9.17 1H, s . Preparation of the object compounds I Example 1 Vilsmeier reagent was prepared from N,N dimethylformamide 0.31 g and phosphorus oxychloride 00.64 g in a usual manner. 2 tert butoxyzarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetic acid syn isomer 1.0 g was added to a stirred suspension of theVilsmeier reagent prepared above in ethyl acetate 11 ml under ice cooling, and the stirring was continued for 30 minutes at the same temperature to produce an activated acid solution. N Trimethylsilylacetamide 3.2 g was added to a stirred suspension of 7 amino 3 cephem 4 carboxylic acid 0.7 g in ethyl acetate C20 ml , and the stirring was continued at 40 to 430C for 30 minutes.To this solution was added the above activated acid solution at 100C, followed by stirring at the same temperature for 30 minutes.Water 10 ml was added to the resultant solution, and the separated organic layer was washed with water, dried over magnesium sulfate and then evaporated to give 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 cephem 4 carboxylic acid syn isomer 1.4 g . IR Nujol 3220, 1780, 1680, 1640, 1540 cm 1 NMR DMSO d6, d 1.40 9H, s , 3.57 2H, m , 4.67 2H, s , 5.07 1H, d, J SHz , 5.87 1H, dd, J 5Hz, 8Hz , 6.43 1H, m , 9.58 1H, d, J 8Hz , 10.25 1H, s .Example 2 Vilsmeier reagent was prepared from phosphorus oxychloride 1.7 g and N,N dimethylformamide 0.8 g in ethyl acetate 3.2 ml in a usual manner. 2 tert Butoxycarbonylmethoxyimino 2 l,2,4 thiadiazol 3 yl acetic acid syn isomer 2.7 g was added to a stirred suspension of the Vilsmeier reagent prepared above in ethyl acetate 30 ml under ice cooling, and the stirring was continued for 40 minutes at the same temperature to produce an activated acid solution.Bis trimethylsilyl urea 5.8 g was added to a stirred suspension of p nitrobenzyl 7 amino 3 chloro 3 cephem4 carboxylate hydrochloride 3.8 g in tetrahydrofuran 40 ml , and the mixture was stirred for 20 minutes at 35 to 400C. To this solution was added the above activated acid solution at 100C, followed by stirring for 20 minutes at the same temperature. After water and ethyl acetate were added to the reaction mixture, the separated organic layer was washed with a saturated aqueous sodium bicarbonate and aqueous sodium chloride, and then dried over magnesium sulfate. The solution was evaporated to give p nitrobenzyl 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylate syn isomer 4.97 g . l IR Nujol 1770, 1720, 1680, 1630 cm NMR DMSO d6, 6 1.43 9H, s , 3.83 2H, m , 4.71 2H, s , 5.25 1H, d, J 5.0Hz , 5.41 2H, s , 5.96 1H, dd, J 5.0Hz, 8.OHz , 7.64 2H, d, J 8.0Hz , 8.20 2H, d, J 8.0Hz , 9.74 1H, d, J 8.0Hz , 10.28 1H, s .Example 3 Benzhydryl 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4carboxylate syn isomer 2.0 g was obtained by reacting benzhydryl 7 amino 3 vinyl 3 cephem 4 carboxylate hydrochloride 1.5 g with an activated acid solution, which was prepared from 2 tert butoxycarbonylmethoxy imino 2 1,2,4 thiadiazol 3 yl acetic acid syn isomer 1.0 g , N,N dimethylformamide 0.31 g and phosphorus oxychloride 0.64 g , according to a similar manner to that of Examples 1 and 2. IR Nujol 3250, 1780, 1720, 1680, 1530 cm NMR DMSO d6, 6 1.43 9H, s , 3.73 2H, ABq, J l8Hz , 4.70 2H, s , 5.25 1H, d, J 5Hz , 5.33 1H, d, J llHz , 5.57 1H, d, J l8Hz , 5.95 1H, dd, J 5Hz, 8Hz , 6.72 1H, dd, J llHz, 18Hz , 6.90 1H, s , 7.33 10H, m , 9.68 1H, d, J 8Hz , 10.23 1H, s .Example 4 A syn isomer of benzhydryl 7 E2 tert butoxycarbonyl methoxyimino 2 1,2,5 thiadiazol 3 yl acetamidol 3 vinyl 3 cephem 4 carboxylate 3.03 g and an anti isomer thereof 1.06 g was separately obtained by reacting benzhydryl 7 amino 3 vinyl 3 cephem 4 carboxylate hydrochloride 4 g with the activated acid solution, which was prepared from 2 tert butoxycarbonylmethoxy imino 2 1,2,5 thiadiazol 3 yl acetic acid a mixture of syn and anti isomers 2.7 g , N,N dimethylformamide 1.14 g and phosphorus oxychloride 2.39 g , according to a similar manner to that of Examples 1 and 2.Syn Isomer IR Nujol 3250, 1770, 1730, 1705, 1665 cm NMR DMSO d6, 1.45 9H, s , 3.58 3.86 2H, m , 4.7 2H, s , 5.23 1H, d, J llHz , 5.25 1H, d, J 5Hz , 5.58 1H, d, J 18Hz , 5.92 1H, dd, J 8Hz, 5Hz , 6.72 1H, dd, J 18Hz, 11Hz , 6.87 1H, s , 7.13 7.5 10H, m , 8.97 1H, s 9.68 1H, d, J 8Hz .Anti Isomer IR Nujol 1770, 1730, 1705, 1665 cm 1 NMR DMSO d6, 6 1.48 9H, s , 3.67 3.98 2H, m , 4.89 2H, s , 5.30 1H, d, J llHz , 5.32 1H, d, J 5Hz , 5.65 1H, d, J 18Hz , 5.92 1H. dd, J 8Hz, 5Hz , 6.80 1H, dd, J 18Hz, 11Hz , 6.97 1H, s , 7.2 7.67 10H, m , 9.33 1H, s , 9.60 1H, d, J 8Hz .Example 5 7 2 tert Butoxycarbonylmethoxyimino 2 1,2,4thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylic acid syn isomer was obtained by reacting 7 amino 3chloro 3 cephem 4 carboxylic acid hydrochloride with the activated acid solution, which was prepared from 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol3 yl acetic acid syn isomer , N,N dimethylformamide and phosphorus oxychloride, according to a similar manner to that of Examples 1 and 2. IR Nujol 1770, 1670 broad cm 1 NMR DMSO d6, 6 1.46 9H, s , 3.82 2H, q, J 18.0Hz , 4.73 2H, s , 5.28 1H, d, J 5.OHz , 5.91 1H, dd, J 5.0Hz, 8.0Hz , 9.73 1H, d, J 8.0Hz , 10.30 1H, s Example 6 Trifluoroacetic acid 3.6 ml was added to a suspension of 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 cephem 4 carboxylic acid syn isomer 1.2 g in anisole 1.2 ml , and the mixture was stirred for 2 hours at ambient temperature. The resultant solution was added dropwise to diisopropyl ether 100 ml and the precipitates were collected by filtration. The precipitates were added to a mixture of water 50 ml and ethyl acetate 50 ml and adjusted to pH 6.5 with 5 aqueous sodium bicarbonate. The separated aqueous layer was adjusted to pH 2.5 with 10 hydrochloric acid and extracted with ethyl acetate.The extract was washed with water, dried over magnesium sulfate and then evaporated to give 7 2 carboxymethoxy imino 2 1,2,4 thiadiazol 3 yl acetamido 3 cephem 4carboxylic acid syn isomer 0.5 g . IR Nujol 3250, 1750, 1720, 1670, 1540 cm 1 NMR DMSO d6, 6 3.58 2H, m , 4.73 2H, s , 5.10 lH, d, J 5Hz , 5.90 1H, dd, J 5Hz, 8Hz , 6.45 1H, m , 9.60 1H, d, J 8Hz , 10.23 1H, s .Example 7 Trifluoroacetic acid 5.2 ml was added to a suspension of 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4carboxylic acid syn isomer 1.3 g in methylene chloride 2.5 ml and anisole 1.3 ml at ambient temperature, and the mixture was stirred for 1.5 hours at the same temperature. To the resultant solution was added a mixture of diisopropyl ether 30 ml and n hexane 15 ml , followed by stirring. The precipitates were collected by filtration and added to a mixture of ethyl acetate and water, followed by adjusting to pH 7.5 with 20 aqueous sodium carbonate.The separated aqueous layer was adjusted to pH 1.8 with 10 hydrochloric acid and saturated with sodium chloride.The resultant aqueous soluiton was extracted with a mixed solvent of ethyl acetate and tetrahydrofuran 2 1 by volume . The extract was washed with a saturated aqueous sodium chloride, dried over magnesium sulfate and then evaporated to give 7 2 carboxy methoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylic acid syn isomer 0.8 g . IR Nujol 1775, 1720, 1680 cm 1 NMR DMSO d6, d 3.82 2H, q, J 19.0Hz , 4.75 2H, s , 5.27 1H, d, J 4.0Hz , 5.91 1H, dd, J 4.0Hz, 8.0Hz , 9.73 1H, d, J 8.OHz , 10.27 1H, s .Example 8 p Nitrobenzyl 7 2 tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylate syn isomer 4.9 g dissolved in a mixed solvent of methanol 30 ml , tetrahydrofuran 30 ml and acetic acid 1 ml . After adding 10 palladium on carbon 2.5 g thereto, the mixture was subjected to catalytic reduction at ambient temperature under atmospheric pressure. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. To the residue were added water and ethyl acetate, and the mixture was adjusted to pH 7.5 with 20 aqueous sodium carbonate. The separated aqueous layer was adjusted to pH 2.0 with 10 hydrochloric acid and then extracted with ethyl acetate. The extract was washed with a saturated aqueous sodium chloride and dried over magnesium sulfate.The solvent was removed by evaporation to give 7 2tert butoxycarbonylmethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 chloro 3 cephem 4 carboxylic acid syn isomer 1.4 g . IR Nujol 1770, 1670 broad cm NMR cDMSO d6, d 1.46 9H, s , 3.82 2H, q, J 18.0Hz , 4.73 2H, s , 5.28 1H, d, J 5.0Hz , 5.91 1H, dd, J 5.0Hz, 8.0Hz , 9.73 1H, d, J 8.0Hz , 10.30 1H, s . Example 9 Trifluoroacetic acid 6.75 ml was added to a solution of benzhydryl 7 2 tert butoxycarbonyl methoxyimino 2 1,2,5 thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4 carboxylate syn isomer 2.9 g in methylene chloride 5.8 ml and anisole 1.9 ml under ice cooling, and the mixture was stirred for 4 hours at ambient temperature. The resultant solution was added dropwise to diisopropyl ether 100 ml and the precipitates were collected by filtration. The precipitates were added to a mixture of water and ethyl acetate and adjusted to pH 7.0 with 10 aqueous sodium hydroxide. The separated aqueous layer was adjusted to pH 2 with 10 hydrochloric acid and extracted with ethyl acetate. The extract was washed with an aqueous sodium chloride and then dried over magnesium sulfate and evaporated in vacuo.The residue was triturated with diisopropyl ether and collected by filtration to give 7 2 carboxymethoxy imino 2 1,2,5 thiadiazol 3 yl acetamido 3 vinyl 3cephem 4 carboxylic acid syn isomer 0.96 g . IR Nujol 3250, 1760, 1680 cm 1 NMR DMSO d6, d 3.5 4 2H, m , 4.85 2H, s , 5.2 1H, d, J 5Hz , 5.27 lH, d, J llHz , 5.55 1H, d, J 18Hz , 5.77 1H, dd, J 8Hz, 5Hz , 6.9 1H, dd, J 18Hz, 11Hz , 9.3 lH, s , 9.53 1H, d, J 8Hz Example 10 7 r2 Carboxymethoxyimino 2 1,2,4 thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4 carboxylic acid syn isomer 1.0 g was obtained by reacting benzhydryl 7 2 tertbutoxycarbonylmethoxyimino 2 1,2,4, thiadiazol 3 yl acetamido 3 vinyl 3 cephem 4 carboxylate syn isomer 1.8 g with trifluoroacetic acid 5.4 ml in the presence of anisole 1.8 ml according to a similar manner to that of Example 9. IR Nujol 3200, 1770, 1680, 1610, 1540 cm 1NMR DMSO d6, 3.72 2H, ABq, J 17Hz , 4.75 2H, s , 5.22 1H, d, J 5Hz , 5.30 lH, d, J llHz , 5.55 1H, d, J 18Hz , 5.83 1H, dd, J 5Hz, 8Hz , 6.92 1H, dd, J llHz, 18Hz , 9.67 1H, d, J 8Hz , 10.27 1H, s .